Jazz Pharmaceuticals delivers extensive late-breaking data at SLEEP 2026, demonstrating real-world impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) on patient outcomes across narcolepsy and idiopathic hypersomnia
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, magnesium, potassium, and sodium… read more.
